Back to rankings

Centene Corp (CNC)

Undervalued
HealthcareHealthcare PlansUnited States

Fundamental

44

Price

$70.17

Market Cap

$34.70B

Part 1 · What the company is worth

Overview

Centene operates as a major healthcare insurer serving primarily government-sponsored programs and vulnerable populations. The company manages healthcare for approximately 28.6 million members across Medicaid, Medicare Advantage, TRICARE, Marketplace insurance, and commercial plans. It operates through a decentralized local model with teams in 30 states for Medicaid and 29 states for Marketplace products, emphasizing culturally sensitive service delivery for low-income, medically complex, and dual-eligible beneficiaries.

How it makes money

Centene generates revenue primarily through premiums received from government programs: Medicaid managed care capitated rates, Medicare Advantage premiums, TRICARE reimbursement, and Marketplace insurance premiums supplemented by federal subsidies. Additional revenue comes from prescription drug plans contracted with CMS, specialty services (pharmacy management, behavioral health, vision and dental), and commercial health insurance offerings. The company earns revenue based on member enrollment and per-member per-month rates negotiated with state and federal payors.

Revenue by segment

Medicaid62%

Medicaid managed care plans serving low-income and vulnerable populations across 30 states with approximately 13 million members. This segment represents the company's largest business line, offering comprehensive healthcare coverage for eligible individuals and families.

Commercial21%

Commercial health insurance plans for employers and individuals, including self-funded administrative services offerings. This segment serves approximately 4.4 million members through a mix of fully insured and self-funded arrangements.

Medicare Advantage14%

Medicare Advantage plans serving seniors aged 65 and older, including prescription drug plans and dual-eligible programs. The company has approximately 1.1 million Medicare members and benefits from positioning to serve dual-eligible beneficiaries facing CMS integration requirements by 2030.

Other3%

Other revenue including Marketplace insurance plans sold through the federally facilitated and state exchanges with subsidies from advanced premium tax credits, TRICARE military healthcare, and specialty services such as pharmacy management and behavioral health offerings.

Competitive moat

Scale · Narrow

Centene's scale advantage derives from being the largest Medicaid insurer (30 states) and largest Marketplace carrier (29 states), giving it negotiating power with providers and states, and enabling investment in technology and care management. However, the moat is narrow because government payors can cut reimbursement rates unilaterally, Medicaid enrollment is policy-dependent, and competitors can enter markets. The company's 40+ years of expertise serving complex low-income populations and its local operating model provide intangible advantages, but these are not sufficient to create a wide competitive moat given regulatory and political risks.

What drives demand

Defensive

Medicaid demand is relatively defensive because it covers low-income and vulnerable populations who maintain healthcare needs regardless of economic cycles. However, total Medicaid enrollment depends on state policy decisions about eligibility and expansion, which can vary. Medicare Advantage and Marketplace demand are also generally non-cyclical since seniors and subsidized consumers continue seeking coverage in recessions. The company's earnings can fluctuate based on medical utilization rates and severity of illness, which may vary by economic conditions, but demand for coverage itself remains stable.

Key risks

  • Medical Cost Management — Failure to accurately estimate and price medical expenses or effectively manage medical costs could materially impact profitability. The company's earnings depend on the accuracy of its actuarial pricing and its ability to control medical utilization and costs relative to premium revenues.
  • Government Reimbursement Rate Risk — Centene derives significant revenue from government programs (Medicaid, Medicare, TRICARE). Government payors can unilaterally reduce reimbursement rates, modify program rules, or change rate-setting methodologies, materially impacting profitability. Policy changes or budget constraints at federal or state levels could reduce rates across all three lines of business.
  • Marketplace Subsidy Dependence — Centene's Marketplace business depends on federal advanced premium tax credits that subsidize consumer premiums. These enhanced subsidies could expire without congressional renewal, making coverage unaffordable for many members and potentially causing enrollment declines and revenue loss.
  • Customer Concentration — Florida and New York Medicaid contracts each represent approximately 10% or more of consolidated Medicaid premium revenues. Loss or significant rate reduction of either contract would materially impact consolidated results. Additionally, dependence on government payors (Medicaid, Medicare, TRICARE) creates concentration risk across the portfolio.
  • Medicaid Disenrollment Risk — Following the expiration of Medicaid continuous enrollment provisions during the Public Health Emergency, states have conducted redeterminations of eligibility. Millions of members have been disenrolled, reducing premium revenues. Centene cannot control state eligibility determinations or re-enrollment timing.
  • Regulatory and Political Uncertainty — Changes to the Affordable Care Act, Medicaid expansion, or Medicare Advantage reimbursement policies could materially affect the company's business. Regulatory investigations or audits by states regarding compliance or billing practices could result in penalties, rate reductions, or contract termination.
  • Debt and Financial Leverage — Centene maintains substantial indebtedness of $23.1 billion in senior notes outstanding as of year-end 2024. High leverage constrains financial flexibility and increases financial risk, particularly if operating earnings decline or if market conditions worsen.
  • Cybersecurity and Systems Integration — Centene relies on complex information systems for claims processing, payment management, and regulatory compliance. Data breaches, system failures, or failed integrations following acquisitions could disrupt operations, result in financial losses, incur remediation costs, or trigger regulatory penalties.

Customer concentration

Top customers account for 20% of revenue

Florida and New York Medicaid contracts each represent approximately 10% or more of consolidated Medicaid premium revenues, meaning the top two customers account for approximately 20% of Medicaid revenues. Beyond these two states, Centene has significant government payors including other state Medicaid programs, Medicare, and TRICARE. The overall customer base is concentrated on government programs: Medicaid, Medicare, and TRICARE together represent the vast majority of revenue, creating dependence on government reimbursement policy.

The case for

Buyers argue that Centene is well-positioned as the dominant Medicaid and Marketplace insurer with proven execution across complex government programs. The company benefits from approximately 28.6 million members and scale advantages that support margin expansion through medical cost management and operational efficiency. The dual-eligible opportunity is compelling: Centene can serve 12+ million dual-eligible beneficiaries and is positioned to benefit from CMS integration requirements by 2030, which will drive higher Medicare revenues. The company has demonstrated strong earnings growth (adjusted EPS of $7.17 in 2024, up from $6.68 in 2023) and operates in a defensive healthcare sector with steady, policy-driven demand for government-sponsored coverage. Its local operating model and deep expertise in managing vulnerable populations create barriers to entry for competitors.

The case against

Sellers fear that Centene faces existential pressure from government rate cuts and policy uncertainty. With 62% of revenue from Medicaid, the company is highly exposed to state budget pressures and political changes that can unilaterally reduce payment rates. The enhanced Marketplace subsidies could expire without renewal, eliminating the economics that made the Marketplace profitable. Florida and New York represent 20% of Medicaid revenues, creating dangerous concentration risk. Post-PHE Medicaid redeterminations have already reduced enrollment, and states may not re-expand eligibility to previous levels, creating a structural revenue headwind. The company carries $23.1 billion in debt, constraining flexibility to weather downturns. Competitors with greater scale (UnitedHealth, Anthem) can cross-subsidize Medicaid with other business lines, while Centene is heavily dependent on government rates. Medical cost management remains unpredictable—utilization trends and medical inflation can quickly erode margins. Regulatory investigations and compliance risks pose ongoing threats to profitability.

Segment figures from fiscal year 2024Sources: Centene Corp Form 10-K for fiscal year ended December 31, 2024

Generated with artificial intelligence on September 21, 2026, shared with all users

Direct competitors

Who this company fights with for the same customers

Compare

Generated with artificial intelligence on September 18, 2026, shared with all users

P/E: 17.2Score: 79Market cap: $93.80B

Elevance is the second-largest Medicaid managed care operator after Centene and also sells marketplace plans under its Anthem brands, so the two compete for the same state contracts and the same individual enrollees.

P/E: 26.8Score: 80Market cap: $360.32B

UnitedHealth's community and state business is one of the Big Five Medicaid plans and it has the widest ACA marketplace footprint of any insurer, overlapping Centene's Medicaid and Ambetter lines in most states.

P/E: 24.7Score: 68Market cap: $119.52B

Through Aetna, CVS Health is one of the five largest Medicaid managed care companies and a direct rival in Medicare Advantage and dual-eligible plans, the same government-funded members Centene serves.

P/E: 45.0Score: 69Market cap: $51.08B

Humana competes with Centene's Wellcare brand for Medicare Advantage and Part D members and bids for the same state Medicaid contracts, though it is far more concentrated on seniors.

Molina Healthcare, Inc.MOH

Molina is Centene's closest business twin: both build their revenue on state Medicaid contracts and ACA marketplace plans for low-income members, and they bid against each other in the same state procurements.

Oscar Health, Inc.OSCR

Oscar sells almost exclusively ACA marketplace plans in twenty states and is the main challenger to Ambetter, Centene's individual-exchange brand.

Balance Sheet & Liquidity

Revenue

$178.66B

Trailing 12 months (through 6/30/2026)

Net Income

$-5.10B

Trailing 12 months (through 6/30/2026)

Free Cash Flow

$4.32B

Total Equity

$19.95B

Total Liabilities

$56.69B

Current Ratio

1.15

Interest Coverage

8.61

Debt/EBITDA

-

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseUndervalued

Fair Value

$152.80

Current Price

$70.17

Margin of Safety

+54.1%

Fair Value Range

$99.32 - $206.28

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$71.78
Discounted cash flow (DCF):$254.08
Earnings multiple (P/E):Not enough data to compute it
Graham growth formula:Not enough data to compute it
Earnings power value (EPV):Not enough data to compute it
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$203.17
Revenue multiple:$1510.41
Last Earnings Surprise:+129.04%

Valuation Metrics

P/E Ratio

-

ROE

-33.4%

P/B Ratio

1.54

P/FCF

3.87

Gross Margin

9.1%

ROIC

-10.5%

Profitability Radar

Value Creation (Economic Moat)

ROIC

-10.5%

WACC

8.2%

ROIC − WACC

-18.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental Analysis Criteria

Passed (11)

  • Price CAGR 9.52%
  • P/FCF 3.87
  • P/B ratio 1.54
  • Debt/equity ratio
  • Positive free cash flow
  • CapEx intensity
  • Current ratio
  • Interest coverage
  • Revenue growth 5Y 24.5%
  • Earnings surprise, average 161.0%
  • Share dilution -5.8%

Failed (10)

  • EPS shows upward trend
  • ROIC -10.5%
  • Gross margin 9.1%
  • Operating margin -3.2%
  • Return on tangible assets
  • Low reliance on intangibles
  • DCF valuation (Fairly Valued)
  • ROE -24.0%
  • Net margin trend -2.9% vs 1.3%
  • Piotroski F-Score 4/9

Unavailable (5)

  • Dividend payout –
  • Debt/EBITDA
  • Price below Graham Number
  • PEG ratio (needs P/E > 0 and growth > 0)
  • Earnings quality (operating cash flow / net income)

Piotroski F-Score

4/9

Mixed signals: some areas need attention

ROA > 0
Operating cash flow > 0
ΔROA > 0
Cash flow > net income
Leverage ↓
Current ratio ↑
No dilution
Gross margin ↑
Asset turnover ↑

Earnings Quality

-

Low quality: investigate accounting

Share Dilution

-5.8%

Buying back shares. Shareholder friendly

Institutional Holdings

Governance

Executive Team

NameTitleAge
Ms. Sarah M. LondonCEO & Director44
Mr. Andrew Lynn AsherExecutive VP & CFO56
Ms. Susan R. SmithChief Operating Officer49
Mr. Christopher Andrew KosterExecutive VP, General Counsel & Secretary60
Ms. Tanya M. McNallySenior VP & Chief People Officer51
Mr. Theodore Joseph PienkosCorporate Controller & Chief Accounting Officer43
Mr. Bradley BolivarChief Information Officer-
Ms. Jennifer Lynch GilliganSenior Vice President of Investor Relations-
Ms. Ashlee KnuckeyChief Risk, Ethics & Compliance Officer-
Sara GarlandChief Communications Officer-

Audit Risk

2

Board Risk

2

Compensation Risk

5

Shareholder Rights Risk

1

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-17

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-07-28

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-10-08

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Part 2 · The price and its context

This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Market Reaction Profile

How much CNC moves, measured on its daily prices.

VolatilityMedium

More volatile than 46% of the tracked stocks (90-day volatility).

Volatility 30d
31.2%
Volatility 90d
34.8%
Beta vs S&P 500 (1y)
0.29Correlation 0.08
Max drawdown (12m)
-32.7%
ATR (14d, % of price)
3.08%

Earnings reactions

How CNC moved around its past quarterly results.

Next earnings release

Oct 27, 2026 · In 3 days · Before the open

EPS estimate: 0.10Revenue estimate: $46.9B

What usually happens

  • Over the last 12 releases the stock moved a median of 4.8% the next day, up or down.
  • Next-day moves: up 6, down 6 (out of 12).
  • Of the 4 releases that beat estimates, the stock fell the next day after 2.

Release history

DateWhen EPS est.EPS actualSurprise Gap 1 day5 days
Jul 27, 2026After the close1.102.51+129.0% -7.1% -0.3% -0.5%
Apr 28, 2026Before the open2.153.37+56.4% +3.0% +14.0% +23.1%
Feb 6, 2026Before the open-1.24-1.19+3.7% -6.7% -3.7% -1.9%
Oct 29, 2025Before the open-0.140.50+454.9% +10.3% +12.5% +8.8%
Jul 25, 2025Before the openn/an/an/a+1.4% +6.1% -2.6%
Apr 25, 2025Before the openn/an/an/a-5.2% -6.3% -3.5%
Feb 3, 2025After the closen/an/an/a-7.1% -5.4% -9.1%
Oct 24, 2024After the closen/an/an/a+13.6% +4.2% +1.0%
Jul 25, 2024After the closen/an/an/a+3.0% +8.5% +15.6%
Apr 25, 2024After the closen/an/an/a-2.3% -2.2% -1.8%
Feb 5, 2024After the closen/an/an/a-0.4% +1.1% +5.2%
Oct 23, 2023After the closen/an/an/a+2.4% -1.7% -4.1%

Release dates from SEC 8-K filings.

Updated 10/24/2026

Historical statistics for educational purposes only. They are not forecasts and not investment advice.

Price reaction to the news

Latest news on CNC and what the price did next.

Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.

Latest News

Recent headlines for CNC.

  • 7/28/2026POSITIVE
    Centene Boosts Guidance, Reports Favorable Medical Costs

    Centene Corporation has raised its annual profit guidance, signaling strong performance in the second quarter. The health insurer's improved outlook comes amid expectations that it can successfully navigate evolving government policies impacting the sector. This upward revision suggests robust operational execution and potentially better-than-anticipated medical cost management, which are key drivers for profitability in the health insurance industry. Investors will likely view this as a positive indicator of the company's resilience and future earnings potential.

  • 6/18/2026NEUTRAL
    If You Invested $100 In Centene Stock 20 Years Ago, You Would Have This Much Today

    An investment of $100 in Centene Corporation (CNC) stock twenty years ago would have yielded a significant return, though the exact figure is not provided in this summary. The article likely details the historical performance of Centene, a major managed care organization, over the past two decades. Investors considering Centene should analyze its long-term growth trajectory, market position within the healthcare sector, and any significant strategic shifts or regulatory challenges it has faced during this period to understand the drivers of its past performance and future potential.

  • 6/16/2026NEGATIVE
    Membership Slump Forces Health Giant Centene Into Staff Buyouts: Report

    Centene Corporation is implementing a significant cost-cutting initiative, offering voluntary buyouts to employees due to a notable decline in health plan enrollment. This move signals financial pressure and a strategic pivot to reduce operational expenses. Investors should monitor the effectiveness of these cost-saving measures and the company's ability to stabilize or grow its membership base in the coming quarters. The success of this plan will be crucial for future profitability and stock performance.

  • 3/25/2026NEUTRAL
    The youngest-ever female Fortune 500 CEO is reinventing the largest Medicaid insurer amid funding cuts and rising costs

    The article highlights the leadership of the youngest-ever female CEO at a Fortune 500 company, who is navigating Centene Corporation, a major Medicaid insurer, through a challenging environment of funding cuts and rising healthcare costs. While the article focuses on the CEO's strategic initiatives and the company's resilience, it does not provide specific financial performance data or forward-looking guidance that would directly impact stock valuation. Investors will be watching for how these strategies translate into tangible financial results in upcoming quarters.

  • 3/15/2026NEGATIVE
    Centene, Paramount Skydance, And Ulta Beauty Are Among Top 10 Large Cap Losers Last Week (March 9-March 13): Are the Others in Your Portfolio?

    Centene Corporation was among the top 10 large-cap decliners last week, with its stock price falling significantly. The broader market saw healthcare, media, beauty, and tech stocks leading the downturn. This decline was attributed to a combination of factors including earnings misses, weak forward-looking guidance provided by companies, downward analyst revisions, and challenging financing conditions. Investors are advised to monitor these headwinds closely as they impact sentiment and stock performance across various sectors.

  • 3/10/2026NEGATIVE
    Obamacare enrollment is plunging as costs soar, pushing down stocks like Centene

    Centene Corporation's stock is facing pressure as enrollment in the Affordable Care Act (ACA), also known as Obamacare, plummets. Soaring costs associated with the ACA are making health insurance plans less attractive, leading to a decline in policyholders. This trend directly impacts health insurers like Centene, which derive a significant portion of their revenue from ACA-compliant plans. The decrease in enrollment suggests lower premium revenues and potentially higher per-member costs for insurers, signaling a challenging financial outlook for the company and potentially others in the managed care sector.